clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-268Research ArticleФАРМАКОЭКОНОМИКАPHARMACOECONOMICSДифференцированный подход к терапии артериальной гипертонии с учетом фармакоэкономики: возможности иАПФОстроумоваО. Д.clinvest@mail.ruНедогодаС. В.clinvest@mail.ruМамаевВ. И.clinvest@mail.ruИщенкоК. А.clinvest@mail.ruФГБОУ ВО «Волгоградский государственный медицинский университет», Россия, ВолгоградRussian Federation200323062018013845Copyright © Остроумова О.Д., Недогода С.В., Мамаев В.И., Ищенко К.А., 20182018Остроумова О.Д., Недогода С.В., Мамаев В.И., Ищенко К.А.Остроумова О.Д., Недогода С.В., Мамаев В.И., Ищенко К.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/268артериальная гипертонияфармакоэкономикаингибиторы АПФReferencesГиляревский С.Р., Орлов В.А. Использование анализа эффективности лечения для принятия клинического решения в кардиологии. Кардиология. 1997;9:70 – 80.Гиляревский С.Р., Орлов В.А. Использование анализа эффективности лечения для принятия клинического решения в кардиологии. Кардиология. 1997;9:70 – 80.Еlliott W.J. CostBeffectiveness of arterial hypertension. Postgrad. Med. 1996; 99: P.241-52.Еlliott W.J. CostBeffectiveness of arterial hypertension. Postgrad. Med. 1996; 99: P.241-52.Flack J.M., Novicov S.V., Ferrario C.M. Benefits of adherence to antiBhypertensive drug therapy. Europ. Heart J.1996;17 (Suppl.):16-20.Flack J.M., Novicov S.V., Ferrario C.M. Benefits of adherence to antiBhypertensive drug therapy. Europ. Heart J.1996;17 (Suppl.):16-20.Drummond M.F. Resource allocation decision in health care: a role for quality of life assessments J. Chron. Dis. 1987;40: 605 –616.Drummond M.F. Resource allocation decision in health care: a role for quality of life assessments J. Chron. Dis. 1987;40: 605 –616.O’Brien B. Principles of economic evaluation for health care programs. J. Rheumatol.;1995:22:1399-1402.O’Brien B. Principles of economic evaluation for health care programs. J. Rheumatol.;1995:22:1399-1402.Jonsson B. Measurement of health outcome and associated costs in cardiovascular disease. Europ. Heart J;1996:17 (Suppl.A): 2-7.Jonsson B. Measurement of health outcome and associated costs in cardiovascular disease. Europ. Heart J;1996:17 (Suppl.A): 2-7.Bowling A. Research methods in health. Investigating health and health services.- BuckinhamBPhiladelphia: Open University Press, 1997.- P. 79-98.Bowling A. Research methods in health. Investigating health and health services.- BuckinhamBPhiladelphia: Open University Press, 1997.- P. 79-98.Lindgren-Furmaga E.M., Schuna A.A., Wolff N.L., Goodfriend T.L. Cost of switching hypertensive patients from enalapril maleate to lisinopril. Am. J. Hosp. Pharm. 1991;.48: 276-279.Lindgren-Furmaga E.M., Schuna A.A., Wolff N.L., Goodfriend T.L. Cost of switching hypertensive patients from enalapril maleate to lisinopril. Am. J. Hosp. Pharm. 1991;.48: 276-279.McDonough K.P., Weaver R.H., Viall G.D. Enalapril to lisinopril: economic impact of a voluntary angiotensinBconverting enzymeBinhibitor substitution program in a staffBmodel health maintenance organization. Ann. Pharmacother. 1992;26:399-404.McDonough K.P., Weaver R.H., Viall G.D. Enalapril to lisinopril: economic impact of a voluntary angiotensinBconverting enzymeBinhibitor substitution program in a staffBmodel health maintenance organization. Ann. Pharmacother. 1992;26:399-404.T.H. Gill, F. Hauter., M.A. Peiter. Conversions from captopril to lisinopril at a dosage ratio 5:1 result in comparable control of hypertension. Ann. Pharmacother. 1996;30:7-11.T.H. Gill, F. Hauter., M.A. Peiter. Conversions from captopril to lisinopril at a dosage ratio 5:1 result in comparable control of hypertension. Ann. Pharmacother. 1996;30:7-11.Doubilet P., Weinstein M.C., McNeil B.J. Use and misuse of the term “Cost effective” in medicine. N. Eng. J. of Med. 1986;314:253-255.Doubilet P., Weinstein M.C., McNeil B.J. Use and misuse of the term “Cost effective” in medicine. N. Eng. J. of Med. 1986;314:253-255.Kuppermann M., Luce B.R., McGovern B. et al. An analysis of the cost effectiveness of the implantable defibrillator. Circulation 1990;8: 91-100.Kuppermann M., Luce B.R., McGovern B. et al. An analysis of the cost effectiveness of the implantable defibrillator. Circulation 1990;8: 91-100.Guyatt G.H. A taxonomy of health status instruments. J. Rheumatol. 1995;22:1188-1190.Guyatt G.H. A taxonomy of health status instruments. J. Rheumatol. 1995;22:1188-1190.Edelson J.T., Weinstein M.C., Tosteson A.N. et al. LongBterm cost effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;236: 407-413.Edelson J.T., Weinstein M.C., Tosteson A.N. et al. LongBterm cost effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;236: 407-413.Croog S.H., Levine S., Testa M.A. et al. The effects of antihypertensive therapy on the quality of life. N. Engl. Med. 1986;314:1657-1664.Croog S.H., Levine S., Testa M.A. et al. The effects of antihypertensive therapy on the quality of life. N. Engl. Med. 1986;314:1657-1664.Mark D.B. Economics of treating heart failure. Am. J. Cardiol. 1997;80:33H-38H.Mark D.B. Economics of treating heart failure. Am. J. Cardiol. 1997;80:33H-38H.Kobelt G. Методы фармакоэкономического анализа: полезность затрат. Клин. фарм. и тер. 1999;3: 60 – 64.Kobelt G. Методы фармакоэкономического анализа: полезность затрат. Клин. фарм. и тер. 1999;3: 60 – 64.Lip G.Y.H., Zarifis V., Beevers M. et al. Eur Heart J. 1995;16: 434.Lip G.Y.H., Zarifis V., Beevers M. et al. Eur Heart J. 1995;16: 434.Евдаков В.А. СоциальноBэкономические аспекты снижения смертности от мозгового инсульта под влиянием вторичной профилактики артериальной гипертонии. Кардиология 1996;.3: 39 - 44.Евдаков В.А. СоциальноBэкономические аспекты снижения смертности от мозгового инсульта под влиянием вторичной профилактики артериальной гипертонии. Кардиология 1996;.3: 39 - 44.Jonsson B.G. CostBbenefit of treating hypertension. J. Hypertens. 1994;12(Suppl.10): S65Bs70.Jonsson B.G. CostBbenefit of treating hypertension. J. Hypertens. 1994;12(Suppl.10): S65Bs70.Kawachi I., Malcolm L.A. The costBeffectiveness of treating mildBtoBmoderate hypertension: a reappraisal. J. Hypertens. 1991;.9: 199-208.Kawachi I., Malcolm L.A. The costBeffectiveness of treating mildBtoBmoderate hypertension: a reappraisal. J. Hypertens. 1991;.9: 199-208.Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics. 1995;7: 242-50.Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics. 1995;7: 242-50.Bulpitt C.J., Fletcher A.E. CostBeffectiveness of the treatment of hypertension. Clin. Exp. Hypertens. 1993; 15: 1131-1146.Bulpitt C.J., Fletcher A.E. CostBeffectiveness of the treatment of hypertension. Clin. Exp. Hypertens. 1993; 15: 1131-1146.Prasad N., Davey P.G., Watson A.D., Peebles L. Safe withdrawal of monotherapy for hypertension is poorly effective and not likely to reduce healthBcare costs. J. Hypertens. 1997; 15: 1519-1526.Prasad N., Davey P.G., Watson A.D., Peebles L. Safe withdrawal of monotherapy for hypertension is poorly effective and not likely to reduce healthBcare costs. J. Hypertens. 1997; 15: 1519-1526.Yarows S.A., Khoury S., Sowers J.R., Cost effectiveness of 24Bhour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension. Am. J. Hypertens. 1994; 7: 464-468.Yarows S.A., Khoury S., Sowers J.R., Cost effectiveness of 24Bhour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension. Am. J. Hypertens. 1994; 7: 464-468.Pierdomenico S.D., Mezzetti A., Lapenna D., Guglielmi M.D. ‘WhiteBcoat’ hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur. Heart. J. 1995; Vol.16: 692-697.Pierdomenico S.D., Mezzetti A., Lapenna D., Guglielmi M.D. ‘WhiteBcoat’ hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur. Heart. J. 1995; Vol.16: 692-697.Fonarow G.C., Walden J.A., Livingston N. et al. Cost effectiveness of speciality care for patients with advanced heart failure. J. of Heart Failure. 1996;3:149.Fonarow G.C., Walden J.A., Livingston N. et al. Cost effectiveness of speciality care for patients with advanced heart failure. J. of Heart Failure. 1996;3:149.Meredith P.A. Theraputic implication of drug “holidays”. Eur. Heart J. 1996; 17 (Suppl.A): 21-24.Meredith P.A. Theraputic implication of drug “holidays”. Eur. Heart J. 1996; 17 (Suppl.A): 21-24.Skaer T.L., Sclar D.A., Robinson L.M. et al. Effect of pharmaceutical formulation for antiBhypertensive therapy on health service utilisation. Clin. Ther. 1993;.15:715-725.Skaer T.L., Sclar D.A., Robinson L.M. et al. Effect of pharmaceutical formulation for antiBhypertensive therapy on health service utilisation. Clin. Ther. 1993;.15:715-725.Nelson E.C., Stason W.B., Neutra R.R., Solomons H.S. Identification of the noncompliant hypertensive patient. Prev. Med. 1980;21: 504-517.Nelson E.C., Stason W.B., Neutra R.R., Solomons H.S. Identification of the noncompliant hypertensive patient. Prev. Med. 1980;21: 504-517.McCombs J.S., Nichol M.B., Newman C.M., Sclar D.A. The cost of interrupting antihypertensive drug therapy in Medicaid population. Med. Care. 1994;32: 214-226.McCombs J.S., Nichol M.B., Newman C.M., Sclar D.A. The cost of interrupting antihypertensive drug therapy in Medicaid population. Med. Care. 1994;32: 214-226.Oster G., Epstein A.M. CostBeffectiveness of antiBhyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA.1987;258: 2381-2387.Oster G., Epstein A.M. CostBeffectiveness of antiBhyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA.1987;258: 2381-2387.Петров В.И., Недогода С.В. Прямые затраты на лечение при гипотензивной терапии ингибиторами АПФ. Проблемы стандартизации в здравоохранении. 1999;№4: 118-119.Петров В.И., Недогода С.В. Прямые затраты на лечение при гипотензивной терапии ингибиторами АПФ. Проблемы стандартизации в здравоохранении. 1999;№4: 118-119.Johannesson M. The costBeffectiveness of the switch towards more expensive antihypertensive drugs. Health Policy. 1994;28:1-13.Johannesson M. The costBeffectiveness of the switch towards more expensive antihypertensive drugs. Health Policy. 1994;28:1-13.Cook J.R., Glick H.A., Gerth W. et al. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. Am. J. Hypertens. 1998;11: 1433-1441.Cook J.R., Glick H.A., Gerth W. et al. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. Am. J. Hypertens. 1998;11: 1433-1441.
The authors declare that there are no conflicts of interest present.